The added value of Real World Evidence – Written by Kavitha Baruah The 58th Annual Scientific Meeting of the British Society for Haematology has had a busy agenda across the last three days. The principal theme for this year’s event was “Better Science, Better Treatment”. Each day’s sessions included content and discussions around the advancement of science…
Read detailsThe Digital Health Technology Show took place between 13th and 14th March at ExCel, London. With over 6000 people in attendance and over 300 exhibitors, this exciting event was the ideal place to learn about the new digital technologies and innovations which are revolutionising the healthcare market within the UK and internationally. There was a wide…
Read detailsIn drug development, from the get go, sponsors focus on how they will ultimately get their products approved. Whilst there are many obstacles to overcome along the way, something that they really need to do is make sure they go out and actually ask the patients what it is that they want for their treatment…
Read detailsMore than 7,000 rare diseases have been identified globally, affecting over 50 million people. In Europe they are defined as diseases that affect 5 in 10,000 lives and are life-threatening or chronically debilitating, whilst in America they are defined as any disease that affects fewer than 200,000 lives. Developing drugs for these rare conditions is…
Read detailsIn order to further strengthen our experience and expertise, OPEN Health has appointed Gavin Jones in the newly created role of Director of Rare Disease. Gavin will work in close partnership with pH Associates and all of the OPEN Health agencies, to drive our existing and future partnership with customers working in this growing area.…
Read detailsTake a look at what our Patient Centred Outcomes team are talking about. We sit down with Angela Rylands, Patient Centred Outcomes Consultant at pH Associates, to take a closer look at how we can bring power to the patient using patient centred outcomes:- WHAT are patient centred outcomes? HOW do we measure patient centred outcomes? WHY are patient centred…
Read detailsMarlena is a Real World Evidence (RWE) Study Set Up Specialist and is responsible for organising HRA, Ethics and local Trust R&D submissions and approvals, centre set up and the ongoing management and close down of study sites. Prior to pH, Marlena worked in a number of CROs in a CTA role and more latterly…
Read detailsOnyinye Diribe is an Associate Management Consultant who works with clients to understand their real-world evidence requirements and subsequently designs and implements projects to address these needs. Onyi works closely with clients from study inception to data publication providing consistent project oversight. Onyi has a broad experience in research both within the National Health Service…
Read detailspH Associates are supporting Cervical Cancer Awareness Week 22-28 January. The theme for 2018 is “Reduce your risk” with Jo’s Cervical Cancer Trust leading the awareness campaign. Each year, over 2800 women are diagnosed with cervical cancer in the UK. Cervical cancer is the most common cancer in women under 35 years of age and…
Read detailsCarly Rich is a Principal Consultant and works across the pH Associates and Harvey Walsh businesses (OPEN Health companies) to input and deliver against the strategic direction of the ‘RWE and Market Access Group’. As a Principal Consultant, Carly works with clients to determine their Real World Data needs and helps them to design bespoke…
Read detailsREAL Europe are looking forward to attending the EUCROF Conference in Vienna on 26-27 February 2018, www.eucrof-conference.eu. The theme of the 2018 Conference ‘Are You Ready to Embrace the Changes’ will underpin the need for knowing, understanding and adhering to the multiple regulatory requirements, guidance documents and systems, which are being released in Europe. The…
Read detailsWe were delighted that our pH Associates’ Patient Centred Outcomes team successfully brought together expert UK endocrinologists and conducted a Delphi panel. This work was the first step to understanding the characteristics considered ‘important’ by UK hypoparathyroidism experts for defining patients with chronic hypoparathyroidism. The results of the panel were recently presented at the Society…
Read details
